Biote announces pricing of secondary offering of common stock

Irving, texas--( business wire )--biote corp. (nasdaq: btmd) (“biote” or the “company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the pricing of an underwritten public offering of its class a common stock by certain of its stockholders at a price to the public of $3.00 per share. the gross proceeds from the offering, before deducting underwriting discounts and commissions, are expected to be $22,173,915. the offering consists of 7,391,305 shares of the company's class a common stock. the selling stockholders have granted the underwriters a 30-day option to purchase an aggregate of not more than 1,108,695 additional shares of the company's class a common stock on the same terms and conditions. the company will not receive any of the proceeds from the sale of the shares offered by the selling stockholders.
BTMD Ratings Summary
BTMD Quant Ranking